PDCD1 and neoplasm: Additionally, novel approaches to safely target 4-1BB co-stimulation to the tumor and circumvent previously observed severe liver toxicity (58) may represent an attractive IO combination strategy to further augment PD-1 and LAG-3 dual blockade.